<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20251208068255N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-02-18</date_registration>
      <primary_sponsor>Researcher</primary_sponsor>
      <public_title>Effect of High-Intensity Interval Training and Omega-3 in Smokers</public_title>
      <acronym></acronym>
      <scientific_title>Effect of Eight Weeks of High-Intensity Interval Training and Omega-3 Supplementation on Inflammatory Variables, Lung Ventilation, and Heart Rate Variability in Young Male Smokers</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-03-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/88194</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: Participants will be allocated to four study groups using block randomization with an equal allocation ratio of 1:1:1:1. The individual participant will be the unit of randomization, and each participant will be independently allocated to one of four groups: high-intensity interval training plus omega-3 supplementation, high-intensity interval training plus placebo, omega-3 supplementation alone, or control plus placebo. The random allocation sequence will be generated using DatInf RandList software, version 1.2. Variable block sizes will be used to maintain balance in the number of participants across the four groups. Stratified randomization will not be used, and no stratification factors will be specified. Allocation concealment will be maintained by an independent researcher who will not be involved in participant recruitment, group allocation, or outcome assessment. The allocation sequence will be concealed using sequentially numbered, opaque, sealed envelopes. After eligibility has been confirmed and enrollment finalized, the corresponding envelope will be opened in numerical order. Outcome assessor blinding will be implemented separately from allocation concealment. The design of the randomization process will be carried out in consultation with an epidemiologist and a statistician.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Tobacco use (smoking).</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group 1: High-Intensity Interval Training (HIIT) Plus Omega-3 Supplementation:                                                                            Participants in this group will complete a 2-week familiarization period followed by an 8-week main HIIT program. Training sessions will be conducted three times per week under the supervision of the researcher and an observer on the running tracks at Sami Abdulrahman Park. Each training session will include a 10-minute warm-up, the main exercise session, and a 10-minute cool-down.During the familiarization period, participants will perform three 300-s running bouts at 60% of maximal aerobic speed (MAS) in week 1 and two sets of three 150-s running bouts at 70% of MAS in week 2. During the 8-week main training program, exercise intensity will increase progressively: 100–110% MAS during weeks 1–2, 110–120% MAS during weeks 3–4, 120–130% MAS during weeks 5–6, and 130–140% MAS during weeks 7–8 of the main training phase. Exercise intensity will also be monitored using the Borg rating of perceived exertion (RPE) scale. Active recovery between repetitions and recovery between sets will follow the approved training protocol.In addition to exercise, participants will receive two fish oil omega-3 capsules daily for 8 weeks (Nutravita Ltd., London, UK). The total daily fish oil dose will be 2,000 mg, providing 1,100 mg of omega-3 fatty acids, including 660 mg of eicosapentaenoic acid (EPA) and 440 mg of docosahexaenoic acid (DHA). One capsule will be taken with or immediately after breakfast, and the second will be taken with the evening meal. Intervention 2: Intervention Group 2: High-Intensity Interval Training (HIIT) Plus Placebo: Participants in this group will complete a 2-week familiarization period followed by the same 8-week main HIIT program as Intervention Group 1. Training sessions will be conducted three times per week under the supervision of the researcher and an observer on the running tracks at Sami Abdulrahman Park. Each training session will include a 10-minute warm-up, the main exercise session, and a 10-minute cool-down. During the familiarization period, participants will perform three 300-s running bouts at 60% of maximal aerobic speed (MAS) in week 1 and two sets of three 150-s running bouts at 70% of MAS in week 2. During the 8-week main training program, exercise intensity will progressively increase from 100% to 140% MAS and will be monitored using the Borg rating of perceived exertion (RPE) scale. Active recovery between repetitions and recovery between sets will follow the approved training protocol. In addition to exercise, participants will receive two placebo capsules daily for 8 weeks. The placebo capsules will be visually identical to the omega-3 capsules and will contain plant-based oil without eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA). One capsule will be taken with or immediately after breakfast, and the second will be taken with the evening meal. Intervention 3: Intervention Group 3: Omega-3 Supplementation Alone:             Participants in this group will receive two fish oil omega-3 capsules daily for 8 weeks (Nutravita Ltd., London, UK). The total daily fish oil dose will be 2,000 mg, providing 1,100 mg of omega-3 fatty acids, including 660 mg of eicosapentaenoic acid (EPA) and 440 mg of docosahexaenoic acid (DHA). One capsule will be taken with or immediately after breakfast, and the second will be taken with the evening meal. Participants will not undertake the HIIT program and will be instructed to maintain their usual daily activities throughout the study. Intervention 4: Control Group: Placebo Without High-Intensity Interval Training (HIIT): Participants in this group will receive two placebo capsules daily for 8 weeks. The placebo capsules will be visually identical to the omega-3 capsules and will contain plant-based oil without eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA). One capsule will be taken with or immediately after breakfast, and the second will be taken with the evening meal. Participants will not undertake the HIIT program and will be instructed to maintain their usual lifestyle and daily activities throughout the study.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is data sharing will be considered after study completion and manuscript preparation.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Badrkhan Rashwan Ismael</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Iran, East Azerbaijan, Tabriz, 29 Bahman Blvd., University of Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5164736931</zip>
        <telephone>+98 935 705 9284</telephone>
        <email>rashwanismael.b@tabrizu.ac.ir</email>
        <affiliation>University of Tabriz</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Elaheh Piralaiy</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Iran, East Azerbaijan, Tabriz, 29 Bahman Blvd., University of Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5164736931</zip>
        <telephone>+98 914 628 5306</telephone>
        <email>epiralaiy@tabrizu.ac.ir</email>
        <affiliation>University of Tabriz</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iraq</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Current male smokers in the city of Erbil, aged 20 to 30.
Smoking more than 20 cigarettes per day.
A history of cigarette smoking for at least 12 months.
A body mass index (BMI) of 18–25 kg/m².
Physician's confirmation of physical health.
No regular exercise or physical activity during the previous six months.</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>30 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>History of diabetes.
History of cardiovascular diseases.
History of respiratory diseases.
History of hypersensitivity or allergy to fish oil, omega-3 fatty acids, or other components of the supplement used in the study.
Use of omega-3 supplements.
Use of other sports or nutritional supplements.
Use of anti-inflammatory medications.
Active intention to quit smoking or to use smoking cessation medications.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z72.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Tobacco use</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group 1: High-Intensity Interval Training (HIIT) Plus Omega-3 Supplementation:                                                                            Participants in this group will complete a 2-week familiarization period followed by an 8-week main HIIT program. Training sessions will be conducted three times per week under the supervision of the researcher and an observer on the running tracks at Sami Abdulrahman Park. Each training session will include a 10-minute warm-up, the main exercise session, and a 10-minute cool-down.During the familiarization period, participants will perform three 300-s running bouts at 60% of maximal aerobic speed (MAS) in week 1 and two sets of three 150-s running bouts at 70% of MAS in week 2. During the 8-week main training program, exercise intensity will increase progressively: 100–110% MAS during weeks 1–2, 110–120% MAS during weeks 3–4, 120–130% MAS during weeks 5–6, and 130–140% MAS during weeks 7–8 of the main training phase. Exercise intensity will also be monitored using the Borg rating of perceived exertion (RPE) scale. Active recovery between repetitions and recovery between sets will follow the approved training protocol.In addition to exercise, participants will receive two fish oil omega-3 capsules daily for 8 weeks (Nutravita Ltd., London, UK). The total daily fish oil dose will be 2,000 mg, providing 1,100 mg of omega-3 fatty acids, including 660 mg of eicosapentaenoic acid (EPA) and 440 mg of docosahexaenoic acid (DHA). One capsule will be taken with or immediately after breakfast, and the second will be taken with the evening meal.</i_keyword>
      <i_keyword>Intervention Group 2: High-Intensity Interval Training (HIIT) Plus Placebo: Participants in this group will complete a 2-week familiarization period followed by the same 8-week main HIIT program as Intervention Group 1. Training sessions will be conducted three times per week under the supervision of the researcher and an observer on the running tracks at Sami Abdulrahman Park. Each training session will include a 10-minute warm-up, the main exercise session, and a 10-minute cool-down. During the familiarization period, participants will perform three 300-s running bouts at 60% of maximal aerobic speed (MAS) in week 1 and two sets of three 150-s running bouts at 70% of MAS in week 2. During the 8-week main training program, exercise intensity will progressively increase from 100% to 140% MAS and will be monitored using the Borg rating of perceived exertion (RPE) scale. Active recovery between repetitions and recovery between sets will follow the approved training protocol. In addition to exercise, participants will receive two placebo capsules daily for 8 weeks. The placebo capsules will be visually identical to the omega-3 capsules and will contain plant-based oil without eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA). One capsule will be taken with or immediately after breakfast, and the second will be taken with the evening meal.</i_keyword>
      <i_keyword>Intervention Group 3: Omega-3 Supplementation Alone:             Participants in this group will receive two fish oil omega-3 capsules daily for 8 weeks (Nutravita Ltd., London, UK). The total daily fish oil dose will be 2,000 mg, providing 1,100 mg of omega-3 fatty acids, including 660 mg of eicosapentaenoic acid (EPA) and 440 mg of docosahexaenoic acid (DHA). One capsule will be taken with or immediately after breakfast, and the second will be taken with the evening meal. Participants will not undertake the HIIT program and will be instructed to maintain their usual daily activities throughout the study.</i_keyword>
      <i_keyword>Control Group: Placebo Without High-Intensity Interval Training (HIIT): Participants in this group will receive two placebo capsules daily for 8 weeks. The placebo capsules will be visually identical to the omega-3 capsules and will contain plant-based oil without eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA). One capsule will be taken with or immediately after breakfast, and the second will be taken with the evening meal. Participants will not undertake the HIIT program and will be instructed to maintain their usual lifestyle and daily activities throughout the study.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Interleukin-6 (IL-6). Timepoint: Primary outcomes will be assessed at two time points: At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: IL-6 levels will be measured using commercial human ELISA kits (Karmania Pars Gene, Iran). This assay will be performed using the sandwich ELISA method, in accordance with the manufacturer’s instructions.</prim_outcome>
      <prim_outcome>C-reactive Protein (CRP). Timepoint: Primary outcomes will be assessed at two time points: At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: Serum CRP concentration will be measured using a quantitative immunoturbidimetric method on an automated clinical chemistry analyzer (Cobas c 311; Roche Diagnostics, Germany).</prim_outcome>
      <prim_outcome>Clara Cell Protein 16 (CC16). Timepoint: Primary outcomes will be assessed at two time points: At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: Serum CC16 levels will be measured using commercial human ELISA kits (ZellBio, Germany). This assay is performed based on the sandwich ELISA method and in accordance with the manufacturer's instructions.</prim_outcome>
      <prim_outcome>Surfactant Protein D (SP-D). Timepoint: Primary outcomes will be assessed at two time points: At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: Serum SP-D levels will be measured using commercial human ELISA kits (ZellBio, Germany). This assay is performed based on the sandwich ELISA method, in accordance with the manufacturer's instructions.</prim_outcome>
      <prim_outcome>Clara Cell Protein 16 (CC16)/Surfactant Protein D (SP-D) Ratio. Timepoint: Primary outcomes will be assessed at two time points: At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: The CC16 to SP-D ratio is calculated by dividing the serum concentration of CC16 by the serum concentration of SP-D.</prim_outcome>
      <prim_outcome>Forced Vital Capacity (FVC). Timepoint: Primary outcomes will be assessed at two time points: At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: FVC measurement will be performed before and after the intervention using a portable spirometer (model GP, manufactured by Micro Medical, UK) and in accordance with standard recommendations. Participants were seated on a chair, a nose clip was applied, and the mouthpiece of the device was placed in the mouth. Following a maximal deep inspiration, they immediately performed a forceful and maximal expiration through the mouthpiece sensor to determine FVC.</prim_outcome>
      <prim_outcome>Forced Expiratory Volume in one Second (FEV₁). Timepoint: Primary outcomes will be assessed at two time points: At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: FEV₁ will be measured before and after the intervention using a portable spirometer (model GP, manufactured by Micro Medical, UK) and in accordance with standard recommendations. Participants were seated, a nose clip was applied, and the mouthpiece was placed in the mouth. After performing a maximal deep inspiration, they immediately executed a rapid and forceful expiration through the mouthpiece. The volume of air exhaled during the first second was recorded as FEV₁.</prim_outcome>
      <prim_outcome>Forced Expiratory Volume in one Second (FEV₁)/Forced Vital Capacity (FVC). Timepoint: Primary outcomes will be assessed at two time points: At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: The ratio of forced expiratory volume in one second to forced vital capacity (FEV₁/FVC) will be calculated by dividing the measured FEV₁ value by the measured FVC value and multiplying the result by 100. Results will be expressed as a percentage (%).</prim_outcome>
      <prim_outcome>Time-domain heart rate variability parameter: Standard Deviation of NN Intervals (SDNN). Timepoint: Primary outcomes will be assessed at two time points: At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: SDNN will be determined from the electrocardiogram (ECG) recording by calculating the standard deviation of all normal-to-normal (NN) intervals during the recording period. Results will be expressed in milliseconds (ms).</prim_outcome>
      <prim_outcome>Time-domain heart rate variability parameter: Root Mean Square of Successive Differences (rMSSD). Timepoint: Primary outcomes will be assessed at two time points: At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: rMSSD will be determined by calculating the square root of the mean of the squared differences between successive NN intervals derived from the ECG recording. Results will be expressed in milliseconds (ms).</prim_outcome>
      <prim_outcome>Frequency-domain heart rate variability parameter: Low-Frequency Power (LF Power). Timepoint: Primary outcomes will be assessed at two time points: At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: Power LF will be calculated by spectral analysis of the NN intervals derived from the ECG recording within the frequency range of 0.04–0.15 Hz. When absolute power is reported, results will be expressed in ms².</prim_outcome>
      <prim_outcome>Frequency-domain heart rate variability parameter: High-Frequency Power (HF Power). Timepoint: Primary outcomes will be assessed at two time points: At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: Power HF will be calculated by spectral analysis of the NN intervals derived from the ECG recording within the frequency range of 0.15–0.40 Hz. When absolute power is reported, results will be expressed in ms².</prim_outcome>
      <prim_outcome>Frequency-domain heart rate variability parameter: Low-Frequency-to-High-Frequency Power Ratio (LF/HF Ratio). Timepoint: Primary outcomes will be assessed at two time points: At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: The LF/HF ratio will be calculated by dividing power LF by power HF and will be reported as a dimensionless value.</prim_outcome>
      <prim_outcome>Maximal Oxygen Uptake (VO₂max). Timepoint: Primary outcomes will be assessed at two time points: At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: After baseline measurements, participants are guided to a standard 400-meter track to perform the Cooper test for estimating VO₂max. In this test, participants are instructed to cover the maximum distance possible within 12 minutes. VO₂max is then estimated based on the distance covered using the following formula:VO₂max (ml/kg/min)=(22.351×distance in kilometers)−11.288VO₂max (ml/kg/min)=(22.351×distance in kilometers)−11.288.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Tumor Necrosis Factor-alpha (TNF-α). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; and after eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: Serum TNF-α levels will be determined using commercial human ELISA kits (Karmania Pars Gene, Iran) based on the sandwich ELISA method.</sec_outcome>
      <sec_outcome>Cortisol. Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; and after eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: Salivary cortisol levels are used as a primary biomarker for assessing physiological stress. To ensure consistency and minimize the influence of daily fluctuations, samples are collected every morning at a fixed time, ideally between 7:00 and 9:00 a.m., when cortisol levels naturally peak. After collection, the samples are stored under appropriate temperature conditions and analyzed using enzyme-linked immunosorbent assay (ELISA) techniques.</sec_outcome>
      <sec_outcome>Peripheral blood oxygen saturation (SpO₂). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; and after eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: SpO₂ will be measured noninvasively using a finger pulse oximeter model Beurer PO 45 (Germany). The device measures oxygenated and deoxygenated hemoglobin in capillary blood using two light wavelengths (red and infrared) and calculates the oxygen saturation percentage based on the light absorption ratio. The sensor is placed on the participant’s dominant index finger, and once the display stabilizes (usually within 5 to 10 seconds), SpO₂ and heart rate values are read from the digital screen and recorded. Measurements are performed at rest in a quiet environment with room temperature between 22 and 25 degrees Celsius to avoid errors caused by movement, cold, or strong light. Each measurement is repeated twice, and the average is recorded as the final SpO₂ value. The normal SpO₂ range in healthy individuals is 95 to 99 percent; however, in non-athletic smokers, a relative reduction in SpO₂ values is expected due to the presence of carbon monoxide and increased carboxyhemoglobin.</sec_outcome>
      <sec_outcome>Total Antioxidant Capacity (TAC). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; and after eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: TAC will be measured using commercially available human ELISA assay kits from (ZellBio, Germany), based on the ferric reducing antioxidant power (FRAP) colorimetric method. TAC concentration will be calculated using a standard curve prepared with ferrous chloride (FeCl₂), in accordance with the manufacturer's instructions.</sec_outcome>
      <sec_outcome>Malondialdehyde (MDA). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; and after eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: MDA will be measured using commercially available human ELISA assay kits from (ZellBio, Germany), based on the thiobarbituric acid-reactive substances (TBARS) method. MDA concentration, as an indicator of lipid peroxidation and oxidative stress, will be determined according to the manufacturer's instructions.</sec_outcome>
      <sec_outcome>High-density lipoprotein cholesterol (HDL-C). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; and after eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: HDL-C will be measured using a standard enzymatic colorimetric method with a Cobas c 311 clinical chemistry analyzer (Roche Diagnostics, Mannheim, Germany). Results will be expressed in milligrams per deciliter (mg/dL).</sec_outcome>
      <sec_outcome>Low-density lipoprotein cholesterol (LDL-C). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; and after eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: LDL-C will be measured using a standard enzymatic colorimetric method with a Cobas c 311 clinical chemistry analyzer (Roche Diagnostics, Mannheim, Germany). Results will be expressed in milligrams per deciliter (mg/dL).</sec_outcome>
      <sec_outcome>Triglyceride (TG). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: TG concentration will be measured using a standard enzymatic colorimetric method with a Cobas c 311 clinical chemistry analyzer (Roche Diagnostics, Mannheim, Germany). Results will be expressed in milligrams per deciliter (mg/dL).</sec_outcome>
      <sec_outcome>Resting heart rate (RHR). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: RHR will be measured using a digital blood pressure monitor (Omron M6 Comfort, Japan) on the left arm. Before measurement, participants will remain seated at rest for 25 minutes. Heart rate will be recorded three times at 5-minute intervals, and the mean of the three measurements will be used as the final RHR value. Results will be expressed in beats per minute (bpm).</sec_outcome>
      <sec_outcome>Systolic blood pressure (SBP). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: SBP will be measured using a digital blood pressure monitor (Omron M6 Comfort, Japan) on the left arm. Before measurement, participants will remain seated at rest for 25 minutes. SBP will be measured three times at 5-minute intervals, and the mean of the three measurements will be used as the final SBP value. Results will be expressed in millimeters of mercury (mmHg).</sec_outcome>
      <sec_outcome>Diastolic blood pressure (DBP). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: DBP will be measured using a digital blood pressure monitor (Omron M6 Comfort, Japan) on the left arm. Before measurement, participants will remain seated at rest for 25 minutes. DBP will be measured three times at 5-minute intervals, and the mean of the three measurements will be used as the final DBP value. Results will be expressed in millimeters of mercury (mmHg).</sec_outcome>
      <sec_outcome>Body weight (kg). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: Body weight will be measured using a digital scale (Seca 890, manufactured in Germany).</sec_outcome>
      <sec_outcome>Body fat percentage. Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; After eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: Body fat percentage will be measured using a body composition analyzer (InBody 270, manufactured in South Korea).</sec_outcome>
      <sec_outcome>Body Mass Index (BMI). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; and after eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: BMI is calculated using the following formula: Body Mass Index (kg/m²) = weight (kg) / square of height (m²).</sec_outcome>
      <sec_outcome>Pittsburgh Sleep Quality Questionnaire (PSQI). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; and after eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: To assess participants’ sleep quality, the Persian version of the PSQI will be used. This self-reported questionnaire includes 19 items divided into seven components: subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Each component is scored from 0 to 3, and the sum of the seven component scores forms the global PSQI score (0–21). A score of ≤5 indicates good sleep quality, while a score &gt;5 indicates poor sleep quality. This tool provides a comprehensive assessment of sleep quality and its impact on daily functioning, and the Persian version has been validated in Iranian studies.</sec_outcome>
      <sec_outcome>Health-related quality of life (HRQOL). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; and after eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: To assess participants’ HRQOL, the WHOQOL-BREF questionnaire will be used. It will be administered before the intervention and after the eight-week intervention. The WHOQOL-BREF evaluates four main domains: physical health, social relationships, psychological status, and environment. Scores for each domain include raw and transformed values, reflecting the individual’s perception of health-related quality of life. In general, higher scores indicate a better understanding of functional health and overall well-being.</sec_outcome>
      <sec_outcome>Patient Health Questionnaire (PHQ). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; and after eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: To assess the severity of depression among participants, the Persian version of the PHQ-9 questionnaire will be used. This self-reported questionnaire consists of 9 items evaluating the individual’s psychological status over the past two weeks, covering components such as decreased interest in activities, feelings of depression, sleep disturbances, fatigue, appetite changes, guilt, concentration problems, psychomotor agitation or retardation, and suicidal thoughts. Each item is scored on a 0 to 3 scale (0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day), and the sum of the 9 items provides the total PHQ-9 score (0–27). This score reflects depression severity: 0–4 minimal, 5–9 mild, 10–14 moderate, 15–19 severe, and 20–27 very severe. The Persian version has been validated and recommended for use in Iranian studies.</sec_outcome>
      <sec_outcome>Perceived Stress Scale (PSS). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; and after eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: The PSS questionnaire will be used to assess the participants' perceived stress levels. This self-reported questionnaire consists of 14 items evaluating the individual’s stress experience over the past month, covering aspects such as sense of control, managing important tasks, dealing with unexpected events, worries, and daily psychological pressure. Each item is scored on a 0-4 scale (0 = never, 1 = almost never, 2 = sometimes, 3 = often, 4 = almost always), and positively worded (reverse) items are reversed before calculating the total score. The sum of the 14 items yields the total PSS score (0–56), with higher scores indicating greater perceived stress. The Persian version has been validated and used in the Iranian population.</sec_outcome>
      <sec_outcome>Fagerström Test for Nicotine Dependence (FTND). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; and after eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: To assess nicotine dependence, the FTND questionnaire will be used. This questionnaire consists of six items about cigarette consumption behavior, with total scores ranging from 0 to 10. Based on the total score, nicotine dependence is classified into three levels: low (0–3), moderate (4–6), and high (7–10). The validity and reliability of the Persian version of this questionnaire were confirmed in the study by Sarbandi et al. (2015), with a reported Cronbach’s alpha of 0.71.</sec_outcome>
      <sec_outcome>COPD Assessment Test (CAT). Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; and after eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: Participants’ symptoms will be recorded using the Chronic Obstructive Pulmonary Disease Assessment Test (CAT). This standard tool includes eight domains, assessing cough, sputum production, chest tightness or heaviness, shortness of breath when climbing stairs or inclines, limitations in daily household activities, sleep quality, and fatigue. The total score reflects the impact of COPD on patients’ daily quality of life, with higher scores indicating greater disease impact.</sec_outcome>
      <sec_outcome>Dyspnea Assessment Test. Timepoint: Secondary outcomes will be assessed at two time points:  At baseline (pre-test), 24 hours before the initiation of any exercise training or omega-3 supplementation; and after eight weeks of intervention (post-test), 48 hours following the completion of the HIIT program and/or omega-3 supplementation. Method of measurement: The severity of dyspnea in participants will be assessed using the Modified Medical Research Council Dyspnea Scale (mMRC). This scale ranges from 0 to 4 and evaluates the impact of shortness of breath on physical activities in patients with respiratory issues. A score of 0 indicates breathlessness only with strenuous activity, while a score of 4 represents severe breathlessness that prevents leaving the house or performing tasks such as dressing and undressing. Participants will indicate the level of activity at which they experience breathlessness.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Researcher</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-12-28</approval_date>
        <contact_name>Research Ethics Committees of University of Tabriz</contact_name>
        <contact_address>Central Library and Documentation Center, University of Tabriz, 29 Bahman Boulevard, Tabriz, East Azerbaijan Province, Iran. Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
